Cho HC, Paik SW, Kim YJ Choi MS, Lee JH, Koh KC, Yoo BC, Son HJ, Kim SW. The seroprevalence of anti-HAV in patients with chronic viral liver disease. World J Gastroenterol 2011; 17 (2): 236-241A research article published in World Journal of Gastroenterology addresses this question. In this study, the authors studied the rate of seroprevalence of the anti-HAV (anti-HAV) in patients with chronic viral liver disease in South Korea. They also sought to determine the seroprevalence by age in these patients to assess whether vaccination against HAV is necessary in all patients who are suffering from liver disease virus and to identify factors that influence anti-HAV IgG seropositivity.

A (HAV) is an important epidemiological distribution of viruses worldwide and causes acute hepatitis in humans. Acute HAV superinfection causes severe liver disease, acute liver failure and even higher rates of mortality in patients with underlying chronic liver disease (CLD). Many studies have identified as a risk factor for CLD and fulminant hepatitis and death from acute infection with HAV.

This study showed that the prevalence of anti-HAV antibodies in Korean patients with chronic viral liver disease was 86.61%, and most patients are over 40 years have already been exposed to HAV. Therefore, vaccination against hepatitis A should be considered, especially for young patients with anti-HAV negative chronic liver disease.

• Previous Entry: People are less likely to buy junk food at the counter